Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for BETASERON
- Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
- Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
- BAY86-5046 (Betaseron), Non Interventional Studies
- Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
- Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
- Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis
- Pulse ACTH vs. MP for MS
- Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.
- Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)
- BEYOND Pilot Study
- Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis
- Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
- BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose
- RNF and Betaseron® Tolerability Study
- An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
- fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls
- Combination Therapy of Betaseron-Prograf in Multiple Sclerosis
- Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
- An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
- Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
- Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
- Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy
- BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study
- Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI
- BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
- Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen
Clinical trials list
click for details